2015 Individual Utilities Vaccination 
FDA Law Blog
AUGUST 21, 2023
Further, FDA has utilized a variety of strategies to call attention to safety issues through Dear Doctor letters or other forms of communication, even if directing changes to labeling is difficult. A recent state law failure-to-warn case in the SDNY makes that very point. But we digress.
FDA Law Blog
SEPTEMBER 14, 2021
The most far reaching drug pricing provision of Subtitle E is an amendment to the Social Security Act to establish a Fair Price Negotiation Program applicable to Medicare Parts B and D as well as group and individual health plans in the commercial market. The Part B rebate would exclude vaccines as well.
Expert insights. Personalized for you.
40 
Let's personalize your content